The $795M Bet on a Brain Channel That Already Failed Once

The early clinical data? Genuinely impressive.

In a randomized, placebo-controlled trial in idiopathic generalized epilepsy (a type of epilepsy affecting the whole brain), patients on opakalim 75 mg went roughly 141 days before experiencing a second major seizure. Patients on placebo? Just 47 days. That's a threefold difference.

Even more striking: 33% of opakalim patients completed the entire 24-week study period without a second generalized tonic-clonic seizure. On placebo, that number was zero percent. Nobody made it through.

In a separate open-label extension study for focal epilepsy, 54% of patients achieved at least a 50% reduction in seizure frequency over six consecutive months. Biohaven has described the drug's tolerability profile as "markedly differentiated" from earlier Kv7 openers, which is a polite way of saying: no, it doesn't turn you blue.

Follow the Money

The deal structure tells you a lot about how confident SK is in this asset. Of the $795 million headline number, $400 million comes in near-term cash: $350 million at closing and another $50 million in 2027. That's more than half the total deal value, paid before most milestones are even triggered.

The remaining $395 million is tied to development and regulatory milestones. Of that, $335 million is specifically for opakalim, with $60 million reserved for other Kv7 compounds and future programs in the platform. Biohaven also gets tiered royalties on U.S. net sales ranging from the mid-teens to low twenties percent.

For Biohaven, this is a financial masterstroke. The company offloads the enormous cost of late-stage development and commercialization while keeping meaningful upside through milestones and royalties. Biohaven's stock jumped roughly 7% to 18% on the news, depending on which session you're tracking.

For SK Biopharmaceuticals, it's a strategic bet that makes their epilepsy franchise much more interesting. Xcopri currently accounts for about 97% of the company's revenue. That kind of concentration is a vulnerability. Adding a second epilepsy drug with a completely different mechanism of action (ion channel modulation vs. Xcopri's sodium channel approach) gives them a broader toolkit and reduces single-product risk.

Korean media described this as the largest in-licensing agreement for an overseas drug candidate ever signed by a Korean pharmaceutical or biotech company.

The Competitive Landscape Is Getting Crowded

SK isn't the only company that sees gold in Kv7 channels. Azetukalner (XEN1101), a competing Kv7.2/7.3 opener, is also in late-stage clinical development. The next-generation Kv7 race is real, and whoever gets to market first with clean data and a tolerable safety profile will have a significant head start.

For context on deal size, this transaction sits comfortably among the largest epilepsy-specific licensing deals of the past two years. Biogen paid $165 million upfront to Stoke Therapeutics for a Dravet syndrome program in 2025. UCB acquired Neurona Therapeutics for up to $1.15 billion, but that was a full acquisition, not a license. The SK-Biohaven deal, at $400 million in near-term cash alone, represents a clear signal that big pharma considers next-generation Kv7 a commercially viable epilepsy strategy.

Why This Deal Matters Beyond Epilepsy

The broader story here is about second acts in drug development. Kv7 was a validated target that got burned by a first-generation drug's side effects. For years, that failure cast a shadow over the entire channel class. Now, with better chemistry and cleaner selectivity, companies are proving that a bad drug doesn't mean a bad target.

SK Biopharmaceuticals is betting $795 million that history won't repeat itself. With opakalim's pivotal RISE3 trial results expected in the second half of 2026, we won't have to wait long to find out if they're right.

The brain's brake pedal is getting a serious upgrade. This time, hopefully without the paint job.

The White House Is Coming for Midsize Biotech's Pricing Power

The White House is reportedly preparing voluntary drug-pricing deals with midsize biotech companies, extending its Most Favored Nation framework beyond Big Pharma for the first time. For companies with concentrated portfolios and thin financial cushions, the implications could be enormous.